Technical Data
B0085-01C
BARD1 (BRCA1 Associated Ring Domain 1)
Description:
BARD1 interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N-terminal ring motif and the C-terminal BRCT domain. The ring motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interation is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer.

Applications:
Suitable for use in Dot Blot, Western Blot and Immunoprecipitation. Other applications have not been tested.

Recommended Dilution:
Western Blot: 0.2-2ug/ml.
Immunoprecipitation: 100-500ug/sample
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
MabIgG18C29Affinity Purified
SizeStorageShippingSourceHost
50ug4°C (-20°C Glycerol)Blue IceHumanMouse
Concentration:
0.05mg/ml
Immunogen:
Synthetic peptide corresponding to aa50-200 from the internal region of human BARD1.
Purity:
Purified by Protein G affinity chromatography.
Form
Supplied as a liquid in PBS, pH 7.4, 1% BSA, 0.05% sodium azide, before the addition of glycerol to 40%.
Specificity:
Recognizes human BARD1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.